Lurtotecan

DB12222InvestigationalSmall molecule

Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).

Formula / weight: C₂₈H₃₀N₄O₆ · 518.57 g/mol (avg)

Resolves to

Compound

UNII4J1L80T08ICAS149882-10-0ChEMBLCHEMBL305666PubChem60956

Structure

InChIKeyRVFGKBWWUQOIOU-NDEPHWFRSA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C4OCCOC4=CC1=C3CN1CCN(C)CC1)C2=O

Targets

P11387TOP1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lurtotecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account